Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 17;7(15):4200–4214. doi: 10.1182/bloodadvances.2022009022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 2. — Circulating MKs upregulate S100A8/A9 in COVID-19. (A) Volcano plot showing 1436 DEGs from scRNA-seq of MKs from severe COVID-19 vs uninfected controls. (B) Expression of S100A8 and S100A9 in MKs from scRNA-seq samples. Two-way ANOVA with Dunnett post hoc multiple comparisons test. All groups compared with uninfected controls. Adjusted P values: ∗P = .05 to .01; ∗∗P = .01 to .001; ∗∗∗P = .001 to .0001; ∗∗∗∗P < .0001. Black asterisks indicate S100A9 statistical comparisons. Red asterisks = S100A8 statistical comparisons. Severe: n = 14; mild-moderate: n = 15; early recovery (<7 days after first negative PCR test): n = 7; late recovery (>14 days after first negative PCR test): n = 5; uninfected: n = 16. (C) Flow cytometry quantification of S100A8/A9 expression in platelets vs MKs (n = 218 patients; 220 samples). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. (D) Flow cytometry plots and quantification of S100A8/A9 expression in circulating MKs from uninfected controls (n = 9 donors) vs COVID-19 (n = 218 patients; 220 samples). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. (E) PrimeFlow flow cytometry showing S100A8/A9 messenger RNA (mRNA) expression by S100A8/A9 protein expression in COVID-19 MKs. Quantification of S100A8/A9 mRNA expression in S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs (n = 3 donors). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. (F) PrimeFlow flow cytometry showing IFITM3 mRNA expression by S100A8/A9 protein expression in COVID-19 MKs. Quantification of IFITM3 mRNA expression in S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs (n = 8 donors). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. (G) Quantification of PrimeFlow IFI27 mRNA expression in S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs (n = 8 donors). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. (H) Representative imaging flow cytometry from FACS-sorted S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs. (I) Histogram showing SSC-A granularity in S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs and quantification of SSC-A granularity in S100A8/A9⁺ MKs vs S100A8/A9⁻ MKs (n = 218 patients; 220 samples). Unpaired 2-tailed t test; ∗∗∗∗P < .0001. All graphs are mean ± SEM. DEGs, differentially expressed genes.